|
Hereditary Sensory Autonomic Neuropathy, Type 5
|
0.800 |
Biomarker
|
disease |
BEFREE |
No mutation in the TRKA (NTRK1) gene encoding a receptor tyrosine kinase for nerve growth factor in a patient with hereditary sensory and autonomic neuropathy type V.
|
12210794 |
2002 |
|
Hereditary Sensory Autonomic Neuropathy, Type 5
|
0.800 |
Biomarker
|
disease |
BEFREE |
These results provide a basis for elucidating the mechanisms underlying the clinical manifestations of HSAN V patients, and provide a basis for the development of "painless" hNGF molecules with therapeutic potential.
|
19945432 |
2010 |
|
Hereditary Sensory Autonomic Neuropathy, Type 5
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Recently a homozygous missense mutation (R100W) in the NGF gene has been identified in HSAN V patients.
|
24494679 |
2014 |
|
Hereditary Sensory Autonomic Neuropathy, Type 5
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
A point mutation (R100W) in the NGFB gene was found in patients with Hereditary Sensory and Autonomic Neuropathy type V (HSAN V), which leads to pain insensitivity.
|
30612733 |
2019 |
|
Hereditary Sensory Autonomic Neuropathy, Type 5
|
0.800 |
Biomarker
|
disease |
BEFREE |
To prevent the NGF pain-inducing collateral effects, thus avoiding the necessity for local brain injection, we developed painless NGF (hNGFp), based on the human genetic disease Hereditary Sensory and Autonomic Neuropathy type V (HSAN V). hNGFp has similar neurotrophic activity as wild type human NGF, but its pain sensitizing activity is tenfold lower.
|
30391352 |
2019 |
|
Hereditary Sensory Autonomic Neuropathy, Type 5
|
0.800 |
Biomarker
|
disease |
BEFREE |
We will review neuropathies and clinical presentations that result from the disruption of NGF signalling in HSAN type IV and HSAN type V and review current advances in developing anti-NGF therapy for the clinical management of pain.
|
23157347 |
2013 |
|
Hereditary Sensory Autonomic Neuropathy, Type 5
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
A missense mutation (R100W) in the beta-NGF gene was found in hereditary sensory autonomic neuropathy V (HSAN V) patients with severe loss of pain perception but without overt cognitive impairment.
|
30524266 |
2018 |
|
Hereditary Sensory Autonomic Neuropathy, Type 5
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Generation of the human induced pluripotent stem cell line UKWNLi002-A from dermal fibroblasts of a woman with a heterozygous c.608 C>T (p.Thr203Met) mutation in exon 3 of the nerve growth factor gene potentially associated with hereditary sensory and autonomic neuropathy type 5.
|
30384131 |
2018 |
|
Hereditary Sensory Autonomic Neuropathy, Type 5
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The physiological function of NGF as a pain mediator is altered in patients with Hereditary Sensory and Autonomic Neuropathy type V (HSAN V), caused by the 661C>T transition in the <i>Ngf</i> gene, resulting in the R100W missense mutation in mature NGF.
|
31685654 |
2019 |
|
Hereditary Sensory Autonomic Neuropathy, Type 5
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We describe a novel NGF mutation in an individual with typical HSAN5 findings.
|
30296891 |
2019 |
|
Hereditary Sensory Autonomic Neuropathy, Type 5
|
0.800 |
Biomarker
|
disease |
BEFREE |
It is concluded that the HSAN4 and HSAN5 phenotypes are parts of a phenotypic spectrum caused by changes in the NGF/TRKA signalling pathway.
|
20978020 |
2011 |
|
Hereditary Sensory Autonomic Neuropathy, Type 5
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
A family with neurological findings similar to hereditary sensory and autonomic neuropathy type V having a point mutation in the nerve growth factor beta (NGFB) gene was recently described.
|
18420729 |
2009 |
|
Hereditary Sensory Autonomic Neuropathy, Type 5
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We have studied a large Swedish family with a mutation in the nerve growth factor beta (NGFB) gene causing insensitivity to deep pain without anhidrosis (hereditary sensory and autonomic neuropathy, type V; HSAN V).
|
15468048 |
2004 |
|
Hereditary Sensory Autonomic Neuropathy, Type 5
|
0.800 |
Biomarker
|
disease |
BEFREE |
The integration of both TrkA and p75<sup>NTR</sup> signaling thus appears to regulate neuroplastic effects of NGF in peripheral nociception.<b>SIGNIFICANCE STATEMENT</b> In the present study, we characterized the naturally occurring nerve growth factor NGF<sup>R100W</sup> mutant that is associated with hereditary sensory and autonomic neuropathy type V. We have demonstrated for the first time that NGF<sup>R100W</sup> retains trophic support capability through TrkA, but fails to engage p75<sup>NTR</sup> signaling pathways.
|
29483280 |
2018 |
|
Hereditary Sensory Autonomic Neuropathy, Type 5
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Although those HSAN V patients associated with the NGF<sup>R100W</sup> mutation suffer from severe loss of deep pain, bone fractures and joint destruction, interestingly patients with the NGF<sup>R100W</sup> mutation do not show apparent cognitive deficits, suggesting important trophic support function is preserved.
|
30632491 |
2019 |
|
Hyperalgesia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
Here we performed long-term evaluation of allodynia and hyperalgesia in a CCI model, and evaluated the effects of NGF and SP on the peripheral and central nervous systems.
|
28685530 |
2017 |
|
Hyperalgesia
|
0.600 |
AlteredExpression
|
phenotype |
BEFREE |
Pressure stimulation, contact heat stimulation, hyperalgesia (pinprick stimulation) and allodynia (brush stimulation) to mechanical stimulation were performed in the area where capsaicin and NGF were injected.
|
29498480 |
2018 |
|
Hyperalgesia
|
0.600 |
GeneticVariation
|
phenotype |
BEFREE |
Intramuscular injection of nerve growth factor (NGF) causes muscle hyperalgesia without immediate pain.
|
30513347 |
2019 |
|
Hyperalgesia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
Nerve growth factor is an inflammatory mediator that induces long-lasting hyperalgesia, which can partially be attributed to nerve growth factor-induced sensitization of primary afferent nociceptors.
|
30387376 |
2019 |
|
Hyperalgesia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
This means that NGF-induced hyperalgesia can occur in the absence of the p75 receptor and suggests that the trkA receptor is sufficient to mediate the acute noxious action of NGF.
|
9835221 |
1998 |
|
Hyperalgesia
|
0.600 |
AlteredExpression
|
phenotype |
BEFREE |
Therefore, this study investigated the effect of NGF on ASIC3 expression in the TNC and the role of NGF signaling in chemical dural stimulation-induced hyperalgesia.
|
30553789 |
2019 |
|
Hyperalgesia
|
0.600 |
GeneticVariation
|
phenotype |
BEFREE |
Local injection of nerve growth factor (3 µg/50 µl) or the TRPV1 agonist capsaicin (1 μg/50 μl), but not neurotrophin-3 injection (1 µg/50 µl), resulted in long-lasting facial heat hyperalgesia, which was both significantly reduced by previous neurotrophin-3 local treatment.
|
31577558 |
2020 |
|
Hyperalgesia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
Hyperalgesia developed after NGF injection in the infrapatellar fat pad, but it was not facilitated by acid provocation.
|
27634419 |
2017 |
|
Hyperalgesia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
Local pre-treatment with anti-NGF or K252a was effective to prevent ET-1 induced heat hyperalgesia.
|
28865353 |
2017 |
|
Hyperalgesia
|
0.600 |
Biomarker
|
phenotype |
BEFREE |
Intraplantar injection of NGF<sup>R100W</sup> into adult rats induced neither TrkA-mediated thermal nor mechanical acute hyperalgesia, but retained the ability to induce chronic hyperalgesia based on agonism for TrkA signaling.
|
29483280 |
2018 |